Controllable "Swiss Army Knife" CAR T Cells Solve Key Efficacy and Safety Issues

Chimeric antigen receptor (CAR)-expressing T cells represent a promising approach to cancer therapy, but safety and efficacy are still major hurdles. Scientists at Boston University and Massachusetts Institute of Technology (MIT) have now developed a new CAR technology, called split, universal, and programmable (SUPRA) CAR, which they claim represents the “Swiss army knife of CAR” and can simultaneously address tumor resistance, prevent immune system overactivation, and enhance speci